Abstract
A long-term study of the effect of cromolyn sodium against bronchial hyperresponsiveness in asthmatic children is described. Cromolyn sodium powder (20 mg), as the capsule formulation, was inhaled by Spinhaler® Turbohaler, tid, for three years. Histamine inhalation tests were performed every 6 months according to the standardized methods of the Japanese Allergy Congress. No other antiasthmatic therapy was given throughout the study except during an acute attack. Bronchial hyperresponsiveness decreased, and clinical symptoms improved throughout the trials. It is suggested that long-term use of cromolyn sodium reduces bronchial hyperresponsiveness concomitant with improved symptomatology in asthmatic children.